Have you ever wondered what a columnist for Pulmonary Fibrosis News does while being hospitalized for 17 days? First, I focused on getting better. Second, I asked many questions of those caring for me. Finally, as I met other medical specialists, I asked them what they knew about…
Pulmonary Fibrosis Foundation adds 2 experts to help guide its future
Celea Therapeutics received $180 million in financing to develop deupirfenidone (LYT-100), an investigational therapy that the company says has the potential to serve as a new standard of care for people with idiopathic pulmonary fibrosis (IPF). The funding will support the planned launch of SURPASS-IPF (NCT07284602), a…
I feel like I’m in a long scene from the classic movie “The Neverending Story,” and the dark force is shingles. As I write this, I’m still hospitalized while my care team works to address the complications of this infection in a post-transplant patient. I’m determined to write this…
Problems in a cell death process called ferroptosis may contribute to the formation of scar tissue in the lungs in idiopathic pulmonary fibrosis (IPF), a study suggests. In ferroptosis, which is an iron-dependent process, reactive oxygen molecules damage cell membranes, leading to cell death. In the study, the researchers described…
A funny thing happened the other day on the way to the Pulmonary Fibrosis News Forums. In the blink of an eye, everything changed, and off I went to the emergency room at Inova Fairfax Hospital in Virginia. I should start at the beginning. On June 12, I began…
My husband, Donnie, suffered from gastroesophageal reflux disease (GERD) for several years before the onset of his lung issues, and we were surprised to learn of the connection between GERD and pulmonary fibrosis (PF). While, to my knowledge, the scientific community isn’t 100% certain of that relationship, we do…
GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a disease with no known cause that’s marked by inflammation and fibrosis, or scarring, that damages the lungs. The developer…
I recently received my first Rituxan (rituximab) infusion. Most people might think of treatment as starting when the medication enters the IV. But for me and many others, it starts long before that, with paperwork, phone calls, authorizations, appointments, and a level of persistence that we patients rarely get credit…
Familial pulmonary fibrosis (FPF) makes up a notable portion of all cases of interstitial lung disease, disorders marked by scarring in the lungs, and tends to appear differently from non-familial versions of the disease, a large, multicenter study has found. While survival outcomes were similar between the two groups,…
